Lazerib 80 Mg (Lazertinib) Tablets

Introduction

Lazerib 80 mg (Lazertinib) is an advanced, third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI). Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, Lazerib is a specialized targeted therapy designed for patients with non-small cell lung cancer (NSCLC). Its highly selective molecular design allows it to target specific cancer-driving mutations while minimizing impact on healthy cells, offering a potent and tolerable treatment option for advanced oncology cases.

Indications

Lazerib 80 mg (Lazertinib) is indicated for:

EGFR-Mutant NSCLC: First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations.
T790M Mutation-Positive NSCLC: Treatment of patients who have progressed on or after prior EGFR TKI therapy and have a confirmed T790M resistance mutation.
CNS Metastasis: Effective for patients whose lung cancer has spread to the brain, due to the drug’s superior blood-brain barrier penetration.

Pharmacology

Lazertinib, the active ingredient in Lazerib, is a small-molecule, irreversible inhibitor of the EGFR kinase.

Mechanism: It selectively binds to the mutant forms of EGFR (Exon 19 del, L858R, and T790M) more effectively than the wild-type (normal) EGFR. This blocks the intracellular signaling pathways that lead to tumor cell survival and uncontrolled growth.
Selectivity: By sparing wild-type EGFR, Lazerib significantly reduces the frequency of typical EGFR-related side effects like severe skin rash and diarrhea, improving patient quality of life.

Dosage & Administration

Oral Administration for Adults:

Standard Dosage: 240 mg (three 80mg tablets) taken orally once daily.
Administration: Tablets should be taken at approximately the same time every day. They can be taken with or without food.
Method: Swallow the tablets whole with water. Do not crush, break, or chew the tablets.
Missed Dose: If a dose is missed by more than 12 hours, skip that dose and take the next scheduled dose as usual.

Drug Interactions

CYP3A4 Inducers: Strong inducers (e.g., Rifampin) can lower Lazertinib levels in the blood, reducing its effectiveness. Avoid co-administration.
CYP3A4 Inhibitors: May increase the concentration of Lazertinib, leading to a higher risk of side effects.
P-gp Inhibitors: May increase the absorption of the drug.
Note: Patients should provide a complete list of current medications to their oncologist before starting Lazerib.

Contraindications

Hypersensitivity: Known hypersensitivity to Lazertinib or any inactive components of the tablet.
Severe Hepatic Impairment: Use with extreme caution and under strict medical supervision in patients with compromised liver function.

Side Effects

Patients receiving Lazerib 80 mg may experience:

Common: Paresthesia (tingling or numbness in hands/feet), rash, and mild diarrhea.
Dermatological: Dry skin, pruritus (itching), or paronychia (nail infection).
Systemic: Fatigue, decreased appetite, and musculoskeletal pain.
Rare but Serious: Interstitial Lung Disease (ILD) or changes in heart rhythm (QT prolongation).

Pregnancy & Lactation

Pregnancy: Lazertinib is not recommended for pregnant women as it may cause fetal harm. Effective contraception is required during and for at least 3 weeks after the final dose.
Lactation: Mothers should avoid breastfeeding while taking Lazerib due to the risk of the drug passing into breast milk.

Precautions & Warnings

Respiratory Monitoring: Patients should report any new or worsening shortness of breath, cough, or fever immediately.
Cardiac Evaluation: Periodic ECG monitoring is recommended to check for QT interval prolongation, especially in patients with existing heart conditions.
Liver Function: Regular blood tests to monitor liver enzymes (ALT, AST, and Bilirubin) are necessary during therapy.

Use in Special Populations

Geriatric Use: No significant differences in safety or efficacy have been observed in elderly patients, but individual monitoring is advised.
Renal Impairment: No dose adjustment is typically needed for mild to moderate renal impairment.

Overdose Effects

Symptoms of overdose may include severe skin reactions or gastrointestinal distress. Management is primarily supportive; there is no specific antidote for Lazertinib.

Storage

Condition: Store at room temperature (15°C to 30°C).
Environment: Keep in a dry, cool place away from direct sunlight. Ensure the container is tightly closed and kept out of reach of children.

Supplier Information

Orio Pharma is a premium pharmaceutical supplier focused on providing high-quality, life-saving oncology medications to the global market. We prioritize reliable logistics and authentic medicine sourcing to ensure patient safety and satisfaction. For supply inquiries, please contact our distribution department.

Manufacturer Information

Lazerib 80 mg is manufactured by Everest Pharmaceuticals Ltd., a leading manufacturer in Bangladesh known for its state-of-the-art facilities and commitment to high-standard generic oncology production.